EMA Lapsed: Trazec (nateglinide) — Novartis Europharm Ltd.

View source ↗

Summary

The EMA page indicates that Trazec (nateglinide) has a lapsed status and is no longer active in the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Trazec (nateglinide)

Snippet

Status: Lapsed. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Novartis Europharm Ltd.. Decision date: 23/07/2007